Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Cash from Financing Activities of $10.9 million for Q1 2026, down 81.5% quarter-over-quarter from $58.8 million in Q4 2025.
Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $10.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $88.0 million (up 345.21% YoY), while the FY2025 annual figure was $77.1 million, up 256.84% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $10.9 million, down from $58.8 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $232.0 million in Q3 2023, with the low at -$481000.0 in Q4 2023.
- The 5-year median for Cash from Financing Activities is $2.7 million (2024), against an average of $28.3 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 3337.63% in 2024, then plunged 108.88% in 2025.
- Neumora Therapeutics' Cash from Financing Activities stood at $26.8 million in 2022, then slumped by 101.79% to -$481000.0 in 2023, then soared by 3337.63% to $15.6 million in 2024, then surged by 277.37% to $58.8 million in 2025, then sank by 81.5% to $10.9 million in 2026.
- Business Quant data shows NMRA's Cash from Financing Activities at $10.9 million in Q1 2026, $58.8 million in Q4 2025, and -$136000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 10.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.88 Mn |
| Mar 31, 2026 | 10.88 Mn |
| Dec 31, 2025 | 58.77 Mn |
| Dec 31, 2025 | 58.77 Mn |
| Sep 30, 2025 | -136,000.00 |
| Sep 30, 2025 | -136,000.00 |
| Jun 30, 2025 | 18.46 Mn |
| Jun 30, 2025 | 18.46 Mn |
| Dec 31, 2024 | 15.57 Mn |
| Dec 31, 2024 | 15.57 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.65 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | -481,000.00 |
| Dec 31, 2023 | -481,000.00 |
| Sep 30, 2023 | 232.02 Mn |
| Sep 30, 2023 | 232.02 Mn |